Ventripoint Diagnostics Ltd.

Toronto, Ontario – The Newswire – September 13,  2023 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT) (OTC:VPTDF) is thrilled to announce that it will be a sponsor for the prestigious 51st Annual Nordic Paediatric Cardiology Meeting being held on September 13th-15th, 2023. The meeting will take place in Helsinki with participants from all over the world.

The event is hosted by the Finnish Cardiac Society, a member of the European society of Cardiology. The Finnish Cardiac Society aims to bring together doctors and other cardiology professionals to support the scientific and practical development of cardiology. There are 11 active working groups within the Finnish Cardiac Society, as well as 34 industrial members representing both device and pharmaceutical companies in the cardiology field.  

The Nordic Paediatric Cardiology Meeting focuses on updating the latest information on significant issues within paediatric cardiology, as well as the advancements of research and treatment. The Meeting will include topics such as new interventions for cardiac heart disease in Nordic countries, artificial intelligence, and telemedicine in congenital heart disease in Nordic countries.

The ideas and research discussed at the Meeting will play a role in further expanding cardiac heart disease research and improving care for patients around the world. This meeting provides a valuable opportunity for Ventripoint to connect with cardiac professionals in the Nordic region, participate in global discussions, and grow its network.


About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Jonathan Robinson



Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.


Copyright (c) 2023 TheNewswire - All rights reserved.